The firms said that the deal will provide access to Tempus' testing menu for healthcare providers at 800 cancer care locations that use Flatiron's OncoEMR platform.

Myriad Genetics and agency partner S50 Health educated OBGYNs and their patients in a campaign called “Getting Ahead of ...

As part of the deal, providers will have access to Tempus' tests such as the xT solid tumor and normal match DNA sequencing test, xR whole-transcriptome sequencing RNA test, liquid biopsy-based xF/xF+ ...